ABSTRACT
Objective:According to the GB/T 15000.3-2008， to develop a fucosterol certified reference material based on the project approved by Standardization Administration. Method:Fucosterol was isolated from <italic>Laminaria japonica</italic> dried thallus via 95% ethanol extraction， vacuum concentration， repeated column chromatography separation， recrystallization in petroleum ether-ethyl acetate， and residual solvent removal. Its chemical structure was identified by elemental analysis （EA）， infrared spectrum （IR）， mass spectrometry （MS）， nuclear magnetic resonance （NMR） and X-ray diffraction （XRD）. Its homogeneity， stability， and cooperative certification conducted by 8 laboratories were carried out by high performance liquid chromatography with evaporative light scattering detector. Result:For the fucosterol reference material， the certified value of purity was 99.54% with expanded uncertainty of 0.16% in confidence interval of 95%， the stability was good within 24 months storage period at 2-4 ℃， which met the technical requirements of reference material and passed the acceptance organized by Standardization Administration. Conclusion:The national standard materials of fucosterol has been successfully developed， which can be used for the determination of this component， the evaluation of detection methods， and the detection and quality control of related products.
ABSTRACT
<p><b>BACKGROUND</b>To evaluate the efficacy and safety of weekly paclitaxel and ifosfamide in the treatment of advanced non-small cell lung cancer.</p><p><b>METHODS</b>Twenty-three patients with advanced non-small cell lung cancer received paclitaxel 50-65 mg/m² IV weekly on days 1, 8, 15, and IFO 1.3 g/m² IV on days 2-4. The schedule was repeated every 28 days for two or three cycles as a course.</p><p><b>RESULTS</b>One patient had complete response and eight had partial response. Eleven patients had stable disease and three had progressive disease. The overall response rate was 39.1%. Twenty patients were followed-up. The 1-year survival was 40%(8/20) and the median survival duration was 8.9 months. The main toxicities were hematological toxicity (leukopenia, 69.6%, 16/23) and nausea/vomiting (47.8%, 11/23).</p><p><b>CONCLUSIONS</b>Combined chemotherapy of weekly paclitaxel and ifosfamide is a good regimen for advanced non-small cell lung cancer with good efficacy and well-tolerated side effects.</p>
ABSTRACT
<p><b>BACKGROUND</b>To evaluate the reversal effect of high dose tamoxifen on multidrug resistance to EP regimen in patients with non-small cell lung cancer.</p><p><b>METHODS</b>A total of 41 patients with NSCLC were studied, who were resistant to EP regimen and were proved to have P-gp protein overexpression. All patients were randomizedly divided into two arms. Reversal group (n=21) received oral tamoxifen 100?mg, 2 times everyday on D1-5, together with EP regimen. Control group (n=20) were only given EP regimen.</p><p><b>RESULTS</b>In reversal group, complete response occurred in 1 patient, and partial response in 5; disease remained stable in 11 patients, and tumor progression occurred in 4 patients. The response rate was 28.6%(6/21). In control group, no response occurred; 9 patients had stable diseases, and the other 11 progressed. There was a significant difference in response rate between the two groups (P=0.012?1). In reversal and control groups, the median survivals were 8.4 and 4.6 months respectively (P < 0.01), and 1-year survial rates were 38.1% and 35.0% respectively. Reversal of P-gp occurred in 7 cases of reversal group (33.3%),and none in control group (P= 0.005?2) . There was no significant difference in toxicities between the two groups (P > 0.05).</p><p><b>CONCLUSIONS</b>High dose tamoxifen can remarkably downregulate the expression of P-gp and partially reverse the multidrug resistance to EP regimen for non-small cell lung cancer.</p>